Spinocerebellar Ataxias
27
2
6
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
7%
2 trials in Phase 3/4
38%
5 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (27)
Use of a New Smartphone Application to Determine Changes in Eyeblink Conditioning From Home Training in Individuals With Spinocerebellar Ataxia
Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
Troriluzole in Adult Participants With Spinocerebellar Ataxia
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
Efficacy of Cerebellar Transcranial Magnetic Stimulation to Treat Hereditary Spinocerebellar Ataxias
Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia
Cycling-Based Priming Coordination Training for Enhancing Ataxia Recovery and Brain Plasticity
Open Pilot Trial of BHV-4157
Stemchymal® for Polyglutamine Spinocerebellar Ataxia
Biomarker Research in Inherited Movement Disorders
rTMS Improves Functions in Spinocerebellar Ataxia
Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients
Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia 38
Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia
Effect of Training on Brain Volume in Ataxia
Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders
Ataxia and Exercise Disease Using MRI and Gait Analysis
RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7